Join our daily newsletter At The Bell to receive exclusive market insights
- Biotech company Immutep (IMM) has provided an update on various trials testing its eftilagimod alpha (efti) cancer drug
- Later this year, the company expects to report final overall survival data from its phase 2b metastatic breast cancer trial
- 54 out of 110 patients have been enrolled in a phase two clinical trial testing the efti drug in first-line, non-small cell lung cancer (NSCLC) patients
- Additionally, Immutep will evaluate efti in combination with its partner, MSD’s, Keytruda (pembrolizumab) drug as a first line therapy for head and neck squamous cell carcinoma (HNSCC) patients
- After ending the March quarter with $51.7 million in cash, Immutep is in a robust financial position
- Immutep ended Friday’s session a slight 1.16 per cent in the red to close at 42.5 cents
Immutep (IMM) has provided an update on its clinical and preclinical programs.
Efti breast cancer trial
The biotechnology company claims it is on track to report the final overall survival (OS) data from a phase 2b metastatic breast cancer trial that is testing the safety and efficacy of its eftilagimod alpha (efti) drug candidate.
The trial has reached around 72 per cent of events, which indicates 72 per cent of total patients with this late-stage cancer had been followed through until death.
Immutep expects to deliver this data to the market in the second half of this year.
TACTI-002 phase two trial
The company is also continuing to enrol patients in its TACTI-002 phase two clinical trial which is also testing the efti drug but for first line non-small cell lung cancer (NSCLC) patients.
Fifty four out of 110 patients are now enrolled and have received at least the first treatment.
Meanwhile, IMM is also recruiting patients with second line NSCLC, which was expanded under a stage two clinical trial design. Currently, 27 out of 36 patients have received the first treatment.
TACTI-003 phase 2b trial
Subject to approval, Immutep will evaluate efti in combination with its collaboration partner’s, Merck & Co. Inc, Kenilworth, NJ, U.S. (MSD) Keytruda (pembrolizumab) drug as a first line therapy for head and neck squamous cell carcinoma (HNSCC) patients.
It will be a randomised, controlled clinical study in about 154 first line HNSCC patients and will take place across Australia, Europe and the U.S. in up to 35 clinical sites.
The primary endpoint of this study is the overall response rate and the secondary endpoints include overall survival and progression-free survival.
After ending the March quarter with $51.7 million in cash, Immutep is in a robust financial position through to 2023.
Immutep ended Friday’s session a slight 1.16 per cent in the red to close at 42.5 cents.
